Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis

• Published in: Arthritis care & research (2010)
• Main Authors: Tarvin, Stacey E, Sherman, Matthew A, Kim, Hanna, Balmuri, Nayimisha, Brown, Amanda G, Chow, Albert, Gewanter, Harry L, de Guzman, Marietta M, Huber, Adam M, Kim, Susan, Klein-Gitelman, Marisa S, Perron, Megan M, Robinson, Angela Byun, Sabbagh, Sara E, Savani, Sonia, Shenoi, Susan, Spitznagle, Jacob, Stingl, Cory, Syverson, Grant, Tory, Heather, Spencer, Charles
• Format: Journal Article
• Language: English
• Published: United States 14.08.2024
• ISSN: 2151-464X; 2151-4658; 2151-4658
• DOI: 10.1002/acr.25393

The objective was to develop consensus treatment plans (CTPs) for patients with refractory moderately severe juvenile dermatomyositis (JDM) treated with biologic disease-modifying antirheumatic drugs (bDMARDs). The Biologics Workgroup of the Childhood Arthritis and Rheumatology Research Alliance JDM Research Committee used case-based surveys, consensus framework, and nominal group technique to produce bDMARD CTPs for patients with refractory moderately severe JDM. Four bDMARD CTPs were proposed: tumor necrosis factor α (TNFα) inhibitor (adalimumab or infliximab), abatacept, rituximab, and tocilizumab. Each CTP has different options for dosing and/or route. Among 76 respondents, consensus was achieved for the proposed CTPs (93% [67 of 72]) as well as for patient characteristics, assessments, outcome measures, and follow-up. By weighted average, respondents indicated that they would most likely administer rituximab, followed by abatacept, TNFα inhibitor, and tocilizumab. CTPs for the administration of bDMARDs in refractory moderately severe JDM were developed using consensus methodology. The implementation of the bDMARD CTPs will lay the groundwork for registry-based prospective comparative effectiveness studies.